Details of Disease

General Information of Disease (ID: DISK3LZD)

Disease Name	Small-cell lung cancer
Synonyms	SCLC1; small cell cancer of the lung; poorly differentiated endocrine neoplasm; SCLC; oat cell carcinoma (morphologic abnormality); oat cell carcinoma; small cell carcinoma of lung; oat cell carcinoma of lung; small cell carcinoma of the lung; small cell neuroendocrine carcinoma of lung; oat cell carcinoma of the lung; oat cell lung carcinoma; small cell lung cancer; small cell neuroendocrine carcinoma of the lung; lung small cell carcinoma; small cell cancer of the lung, somatic; lung oat cell carcinoma; small-cell cancer of lung; lung small cell neuroendocrine carcinoma
Disease Class	2C25: Lung cancer
Definition	Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized byrapid growth, and early metastasis. SCLC usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, and neurological and endocrine paraneoplastic syndromes. SCLC is primarily reported in elderly people with a history of long-term tobacco exposure.
Disease Hierarchy	DIS0167R: Metastatic lung cancer DISYKSRF: Genetic disease DISLTBIC: Lung neuroendocrine neoplasm DIS9S7JY: Small cell carcinoma DISK3LZD: Small-cell lung cancer
ICD Code	ICD-11 ICD-11: 2C25.Y
Disease Identifiers	MONDO ID MONDO_0008433 MESH ID D055752 UMLS CUI C0149925 OMIM ID 182280 MedGen ID 57450 HPO ID HP:0030357 Orphanet ID 70573 SNOMED CT ID 254632001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Belotecan hydrocholoride	DM3SRJZ	Approved	NA	[2]
Carboplatin	DMG281S	Approved	Small molecular drug	[3]
Carfilzomib	DM48K0X	Approved	Small molecular drug	[1]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[4]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[5]
Etoposide	DMNH3PG	Approved	Small molecular drug	[6]
Lurbinectedin	DMEFRTZ	Approved	Small molecular drug	[7]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[1]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[1]
Pemetrexed	DMMX2E6	Approved	Small molecular drug	[8]
Topetecan	DMAE6LK	Approved	Small molecular drug	[9]
Topotecan	DMP6G8T	Approved	Small molecular drug	[10]
Trilaciclib	DMP5A4T	Approved	NA	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 Drug(s)

This Disease is Treated as An Indication in 35 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AL-60371	DMNJT7Y	Phase 3	NA	[12]
Aldoxorubicin	DMHKCIS	Phase 3	NA	[1]
Amrubicin	DM6SGUB	Phase 3	Small molecular drug	[13]
Belagenpumatucel-L	DMQG7ZM	Phase 3	Vaccine	[14]
MLN8237	DMO8PT9	Phase 3	Small molecular drug	[15]
Picoplatin	DM0PIY6	Phase 3	Small molecular drug	[16]
Rova-T	DMNGCAD	Phase 3	NA	[15]
RRx-001	DMQM2FH	Phase 3	Small molecular drug	[17]
Dinutuximab	DMWBWNG	Phase 2/3	NA	[18]
AEB1102	DMB5CKZ	Phase 2	NA	[1]
AZD2811	DMYUNXP	Phase 2	Small molecular drug	[19]
AZD6738	DM0PFNC	Phase 2	Small molecular drug	[20]
BMS-986012	DMVJXOH	Phase 2	Antibody	[21]
DS-3201b	DMI69E5	Phase 2	Small molecular drug	[22]
LY2606368	DM4XMF7	Phase 2	NA	[1]
Nivatrotamab	DMAOUZV	Phase 2	Antibody	[23]
NTX-010	DMKMOF9	Phase 2	NA	[24]
Pentacea	DMGY5JC	Phase 2	Antibody	[25]
SGN-LIV1A	DMA4LNE	Phase 2	Antibody drug conjugate	[26]
Tarextumab	DM95FR3	Phase 2	Monoclonal antibody	[18]
Tarlatamab	DME33OU	Phase 2	Bispecific T-cell engager	[27]
APG-1252	DM8O3R9	Phase 1/2	Small molecular drug	[28]
BNT411	DMGF2PU	Phase 1/2	Small molecular drug	[29]
HPN328	DM1ZHML	Phase 1/2	NA	[30]
INCB59872	DMRLV7G	Phase 1/2	NA	[1]
P2045	DMM2M1L	Phase 1/2	NA	[31]
PEN-221	DMMAUOK	Phase 1/2	NA	[1]
SC16LD6.5	DMQ7UH7	Phase 1/2	NA	[32]
ABBV-011	DMDY117	Phase 1	Antibody drug conjugate	[33]
AMG 119	DMKF1O2	Phase 1	CAR T Cell Therapy	[34]
AMG 757	DMLYP2N	Phase 1	Antibody	[1]
GSK2879552	DMT3V2W	Phase 1	NA	[35]
PF-06821497	DML3WT6	Phase 1	Small molecular drug	[36]
PF-07104091	DMMJZ2E	Phase 1	Small molecular drug	[37]
SC-002	DMZ3HD1	Phase 1	NA	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 35 Drug(s)

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BAY 10-00394	DMV2DIW	Discontinued in Phase 2	Small molecular drug	[38]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
COTI-219	DMJKKVX	Investigative	NA	[39]
COTI-4A	DMGR0EE	Investigative	NA	[39]
COTI-58	DM5JEYD	Investigative	NA	[39]
ET-007	DM036RW	Investigative	NA	[39]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 164 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BMP6	TT07RIB	Limited	Genetic Variation	[41]
CCK	TT90CMU	Limited	Biomarker	[42]
CHRNA5	TTH2QRX	Limited	Genetic Variation	[41]
CHRNB4	TTTVAFQ	Limited	Genetic Variation	[41]
DDR2	TTU98HG	Limited	Genetic Variation	[43]
GLRA1	TTF45NW	Limited	Altered Expression	[44]
GRM8	TT0IFKL	Limited	Biomarker	[45]
IL15	TTJFA35	Limited	Biomarker	[46]
IL33	TT5MD4P	Limited	Genetic Variation	[41]
KDM1A	TTNR0UQ	Limited	Biomarker	[47]
LAMB3	TT2WOUQ	Limited	Altered Expression	[48]
LANCL1	TTZW8NS	Limited	Altered Expression	[49]
MGMT	TTJ8DV7	Limited	Biomarker	[50]
MSTN	TTM8I2X	Limited	Biomarker	[51]
OXTR	TTSCIUP	Limited	Altered Expression	[52]
PAX5	TTA4REJ	Limited	Altered Expression	[53]
PLK1	TTH4IP0	Limited	Biomarker	[54]
PTN	TTA9EJK	Limited	Biomarker	[55]
RPE65	TTBOH16	Limited	Altered Expression	[56]
SCARB1	TTRE324	Limited	Altered Expression	[57]
SCG3	TTY5R9H	Limited	Biomarker	[58]
SLIT2	TTDWK85	Limited	Biomarker	[59]
SMARCA4	TTVQEZS	Limited	Biomarker	[60]
SOX2	TTCNOT6	Limited	Biomarker	[61]
CRYZ	TTP6UO8	Disputed	Altered Expression	[62]
GCLM	TTNFESW	Disputed	Altered Expression	[63]
ADCY1	TTV1ZSQ	moderate	Biomarker	[45]
APOC3	TTXOZQ1	moderate	Biomarker	[64]
ATAD2	TT9A0HI	moderate	Altered Expression	[65]
ATP1A2	TT5B6HJ	moderate	Genetic Variation	[66]
BMX	TTN2I9E	moderate	Biomarker	[67]
BRSK2	TTHZN4X	moderate	Biomarker	[68]
CA1	TTHQPL7	moderate	Altered Expression	[69]
CASP7	TTM7Y45	moderate	Genetic Variation	[70]
CCNE2	TTLDRGX	moderate	Altered Expression	[71]
CD248	TTYJWT7	moderate	Biomarker	[72]
CDH5	TTXLCFO	moderate	Biomarker	[73]
CHRNA4	TT4H1MQ	moderate	Altered Expression	[74]
CNTN1	TTPR8FK	moderate	Biomarker	[75]
CSF3	TT5TQ2W	moderate	Therapeutic	[76]
CYP2A6	TTAQ6ZW	moderate	Altered Expression	[77]
DHODH	TTLVP78	moderate	Biomarker	[78]
EML4	TT92GY4	moderate	Biomarker	[79]
EP300	TTGH73N	moderate	Biomarker	[59]
EPHA7	TTAHTVG	moderate	Biomarker	[59]
EREG	TTYSB89	moderate	Biomarker	[80]
EZH1	TTNJA0C	moderate	Altered Expression	[81]
FYN	TT2B9KF	moderate	Biomarker	[82]
GALR2	TTBPW3J	moderate	Biomarker	[83]
GRIK3	TTNP6O2	moderate	Biomarker	[45]
KAT6B	TTH4VJL	moderate	Altered Expression	[84]
KDM5A	TTIG67W	moderate	Biomarker	[85]
KLK8	TTH5MRS	moderate	Altered Expression	[86]
KMT2A	TT1GNDM	moderate	Biomarker	[59]
LAPTM4B	TTEJQT0	moderate	Altered Expression	[87]
LILRB1	TTC0QRJ	moderate	Biomarker	[88]
MAGEA2	TTOZT28	moderate	Biomarker	[89]
MSR1	TT2TDH9	moderate	Biomarker	[90]
NAPRT	TTVR1FW	moderate	Biomarker	[91]
OTC	TT5KIO9	moderate	Altered Expression	[92]
PPP3CA	TTA4LDE	moderate	Altered Expression	[93]
PTPRZ1	TT4SEA8	moderate	Biomarker	[94]
RRM1	TTWP0NS	moderate	Altered Expression	[95]
RTN4R	TTVRZUO	moderate	Biomarker	[96]
SLC3A2	TT5CZSM	moderate	Altered Expression	[97]
SLC5A4	TTN7Y4P	moderate	Genetic Variation	[98]
SLCO4A1	TTV1YIE	moderate	Biomarker	[99]
SST	TTWF7UG	moderate	Biomarker	[100]
SSTR2	TTZ6T9E	moderate	Genetic Variation	[101]
SSTR5	TT2BC4G	moderate	Biomarker	[102]
TRPA1	TTELV3W	moderate	Biomarker	[103]
TRPC7	TT06GRA	moderate	Biomarker	[104]
UTS2R	TTW5UDX	moderate	Genetic Variation	[105]
ABCC1	TTOI92F	Strong	Biomarker	[106]
ABCC4	TTUEAFL	Strong	Biomarker	[107]
AKR1B1	TTFBNVI	Strong	Biomarker	[108]
AKT1	TTWTSCV	Strong	Posttranslational Modification	[109]
ALK	TTPMQSO	Strong	Biomarker	[110]
APEH	TTYWEDQ	Strong	Genetic Variation	[111]
AURKB	TT9RTBL	Strong	Biomarker	[112]
AVP	TTJ8EWH	Strong	Biomarker	[113]
AVPR1A	TT4TFGN	Strong	Altered Expression	[114]
AVPR1B	TTL9MHW	Strong	Biomarker	[114]
B2M	TTY7FKA	Strong	Genetic Variation	[115]
BCL2L2	TTQ79W8	Strong	Biomarker	[116]
CALCA	TTVSFJW	Strong	Biomarker	[117]
CASP10	TTX5HEK	Strong	Altered Expression	[118]
CBR1	TTVG0SN	Strong	Genetic Variation	[119]
CCKBR	TTVFO0U	Strong	Altered Expression	[120]
CD274	TT8ZLTI	Strong	Biomarker	[121]
CD9	TTZEIBV	Strong	Biomarker	[122]
CDC25A	TTLZS4Q	Strong	Altered Expression	[123]
CDK2	TT7HF4W	Strong	Biomarker	[124]
CDK7	TTQYF7G	Strong	Genetic Variation	[125]
CEACAM3	TTPX7I5	Strong	Biomarker	[126]
CEACAM5	TTY6DTE	Strong	Biomarker	[126]
CGB3	TTUH273	Strong	Biomarker	[127]
CHEK1	TTTU902	Strong	Biomarker	[128]
CNTN2	TT2Z1WB	Strong	Biomarker	[129]
CPB2	TTP18AY	Strong	Altered Expression	[130]
CPE	TTXPWO6	Strong	Genetic Variation	[131]
CREBBP	TTFRCTK	Strong	Biomarker	[132]
DIABLO	TTN74LE	Strong	Biomarker	[133]
EBI3	TTJF68X	Strong	Biomarker	[134]
ELK3	TT5OJMV	Strong	Genetic Variation	[135]
EPHA3	TTHS2LR	Strong	Biomarker	[136]
EPHB1	TT8MDAC	Strong	Genetic Variation	[135]
FDXR	TT3W4IX	Strong	Biomarker	[108]
FGFR1	TTRLW2X	Strong	Biomarker	[137]
FHIT	TTMS54D	Strong	Genetic Variation	[138]
GAL	TTXZAJ5	Strong	Biomarker	[139]
GAST	TT4LRVO	Strong	Altered Expression	[140]
GPRC5D	TTHRAPJ	Strong	Altered Expression	[141]
GRPR	TTC1MVT	Strong	Altered Expression	[142]
HDC	TTV9GOF	Strong	Biomarker	[143]
HSP90AA1	TT78R5H	Strong	Altered Expression	[144]
HTATIP2	TTC6IX5	Strong	Biomarker	[145]
ID2	TTW8A5N	Strong	Biomarker	[146]
KCNJ2	TTH7UO3	Strong	Altered Expression	[88]
KRT19	TT3JF9E	Strong	Altered Expression	[147]
LIN28A	TTO50LN	Strong	Altered Expression	[148]
LRP1	TTF2V7I	Strong	Biomarker	[149]
MAD1L1	TTNE9U7	Strong	Biomarker	[150]
MAGEA1	TT63M7Q	Strong	Altered Expression	[151]
MAGEA3	TTWSKHD	Strong	Biomarker	[152]
MCL1	TTL53M6	Strong	Biomarker	[153]
MELK	TTBZOTY	Strong	Biomarker	[154]
NCAM1	TTVXPHT	Strong	Biomarker	[155]
PCSK1	TTED9LZ	Strong	Altered Expression	[156]
PDCD1	TTNBFWK	Strong	Biomarker	[121]
PDGFRA	TT8FYO9	Strong	Altered Expression	[157]
PLAUR	TTNOSTX	Strong	Biomarker	[158]
PRKDC	TTK3PY9	Strong	Genetic Variation	[159]
PSMB9	TTOUSTQ	Strong	Biomarker	[160]
PTK2B	TTTEFBV	Strong	Biomarker	[161]
RALBP1	TTVSRUA	Strong	Biomarker	[162]
RASA1	TTPNZ1F	Strong	Biomarker	[163]
RBPJ	TT72D4Z	Strong	Biomarker	[164]
RCVRN	TTDQTEY	Strong	Altered Expression	[165]
RGS6	TTJ96M8	Strong	Biomarker	[163]
RICTOR	TT143WL	Strong	Biomarker	[166]
RPSA	TTLUW5B	Strong	Altered Expression	[49]
RTN4	TT7GXMU	Strong	Altered Expression	[167]
SCGB1A1	TTONPVW	Strong	Biomarker	[168]
SLC44A4	TT0NYDG	Strong	Biomarker	[169]
SLC6A2	TTAWNKZ	Strong	Genetic Variation	[135]
SPN	TTOZAX0	Strong	Altered Expression	[170]
SSTR1	TTIND6G	Strong	Biomarker	[102]
STK33	TTP34DQ	Strong	Altered Expression	[171]
TAP1	TT7JZI8	Strong	Biomarker	[172]
TGM1	TT7A949	Strong	Altered Expression	[173]
THRA	TTTSEPU	Strong	Genetic Variation	[174]
THRB	TTGER3L	Strong	Altered Expression	[175]
TOP2B	TT4NVEM	Strong	Altered Expression	[176]
TSG101	TTHU7JA	Strong	Biomarker	[177]
WEE1	TTJFOAL	Strong	Biomarker	[178]
BRCA2	TTUARD6	Definitive	Genetic Variation	[179]
CD24	TTCTYNP	Definitive	Altered Expression	[180]
DDC	TTN451K	Definitive	Genetic Variation	[181]
E2F1	TTASI04	Definitive	Altered Expression	[182]
FPR1	TT5Y4EM	Definitive	Altered Expression	[183]
MDM4	TT9OUDQ	Definitive	Biomarker	[105]
TMPRSS2	TT1GM2Z	Definitive	Genetic Variation	[184]
TOP2A	TTCGY2K	Definitive	Biomarker	[154]
------------------------------------------------------------------------------------


⏷ Show the Full List of 164 DTT(s)

This Disease Is Related to 7 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA2	DTJ4NEG	moderate	Altered Expression	[185]
ATP7A	DT0LT17	moderate	Biomarker	[186]
SLC14A2	DT8QC7K	moderate	Genetic Variation	[105]
SLCO5A1	DTYVQ5M	moderate	Biomarker	[99]
ABCC11	DTWN7FC	Strong	Biomarker	[187]
ABCC5	DTYVM24	Strong	Altered Expression	[188]
SLC4A9	DTSQY0W	Definitive	Biomarker	[189]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DTP(s)

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C1	DE7P2FB	moderate	Biomarker	[190]
ME1	DE97WM8	moderate	Altered Expression	[191]
CHST3	DEQIZP2	Strong	Altered Expression	[192]
UGT1A10	DEL5N6Y	Strong	Biomarker	[193]
------------------------------------------------------------------------------------

This Disease Is Related to 275 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAD2	OTFDSW33	Limited	Genetic Variation	[41]
ADAMTSL1	OTBNYF3F	Limited	Genetic Variation	[41]
ADGRV1	OTLVXHHP	Limited	Genetic Variation	[41]
ASCL1	OTI4X44G	Limited	Biomarker	[181]
ATOH1	OTBZYG2R	Limited	Altered Expression	[194]
BCL2L11	OTNQQWFJ	Limited	Altered Expression	[195]
BTN3A1	OTGZADIX	Limited	Genetic Variation	[41]
CCT2	OTW1VV4E	Limited	Biomarker	[196]
CDYL	OTCUK5KZ	Limited	Biomarker	[197]
CKAP4	OTDUC9ME	Limited	Altered Expression	[56]
COL22A1	OTSWGZRD	Limited	Biomarker	[45]
COL4A2	OTJK1LKN	Limited	Biomarker	[45]
CORIN	OT4SK7DK	Limited	Biomarker	[198]
DMBT1	OTVNU9D9	Limited	Altered Expression	[199]
ELAVL3	OTI2VI8B	Limited	Biomarker	[200]
FLOT2	OTZ0QR5L	Limited	Altered Expression	[201]
H2AZ1	OT3KJJNQ	Limited	Biomarker	[202]
HYAL2	OTTVINXW	Limited	Altered Expression	[203]
HYAL3	OTG6VUSP	Limited	Altered Expression	[203]
INSM1	OTG8RV8E	Limited	Biomarker	[155]
KHSRP	OTDHZARB	Limited	Biomarker	[204]
MAX	OTKZ0YKM	Limited	Biomarker	[205]
MBD2	OTUQPP0R	Limited	Altered Expression	[206]
MEST	OT8Q4U8Y	Limited	Biomarker	[207]
MSH3	OTD3YPVL	Limited	Biomarker	[208]
MST1	OTOC4UNG	Limited	Altered Expression	[209]
MYCL	OT1MFQ5U	Limited	Altered Expression	[210]
MYO18B	OTGYY4NK	Limited	Altered Expression	[211]
NEUROD4	OTGYOIOJ	Limited	Altered Expression	[194]
NMBR	OTBJEGPN	Limited	Biomarker	[212]
NSD3	OT3677ZG	Limited	Biomarker	[213]
NTS	OTPGDNQS	Limited	Biomarker	[214]
PIK3C2B	OTY2PROB	Limited	Altered Expression	[215]
PLEKHM2	OT4ZYV73	Limited	Biomarker	[110]
PLPP5	OTHT51D6	Limited	Biomarker	[213]
PPFIA4	OTWXG0DO	Limited	Biomarker	[216]
RABEPK	OTCZSREH	Limited	Altered Expression	[49]
RB1	OT9VMY7B	Limited	Altered Expression	[217]
REST	OTLL92LQ	Limited	Biomarker	[218]
SFTPA1	OT87XL1U	Limited	Altered Expression	[219]
SFTPA2	OT6SFOMU	Limited	Altered Expression	[219]
SFTPC	OTIZJD09	Limited	Altered Expression	[219]
SLFN11	OTJWFPMY	Limited	Biomarker	[220]
STING1	OTDAP4G0	Limited	Biomarker	[128]
TAF1L	OT9Z7EVA	Limited	Genetic Variation	[66]
TMA16	OTDJXF99	Limited	Genetic Variation	[41]
TMEM132D	OTV6I4Z0	Limited	Biomarker	[221]
TP73	OT0LUO47	Limited	SomaticCausalMutation	[222]
CABIN1	OT4G5CIK	Disputed	Biomarker	[223]
DPYSL5	OT6F9T6F	Disputed	Genetic Variation	[224]
PTPRD	OTZPJ3GX	Disputed	Genetic Variation	[225]
ABCE1	OTH19LOA	moderate	Biomarker	[226]
ADAM12	OTZKOTDB	moderate	Altered Expression	[227]
ADGRB3	OT1EWGRW	moderate	Biomarker	[228]
AJUBA	OTNW7YPK	moderate	Biomarker	[229]
ARMH1	OTTJC0D6	moderate	Altered Expression	[49]
ASH1L	OTUT5NLJ	moderate	Biomarker	[230]
BCLAF1	OT7T8H6A	moderate	Biomarker	[45]
CAST	OTBXZZGF	moderate	Biomarker	[231]
CENPF	OT7AG0SW	moderate	Biomarker	[154]
CIZ1	OT3UKHPI	moderate	Altered Expression	[232]
CMIP	OTZN8Z4A	moderate	Biomarker	[233]
CNNM1	OTHRSSGH	moderate	Genetic Variation	[66]
CNTNAP2	OT48T2ZP	moderate	Biomarker	[45]
COTL1	OT6YCNLF	moderate	Biomarker	[69]
CRACD	OTII2U6L	moderate	Biomarker	[234]
CUL5	OTMTZD47	moderate	Biomarker	[235]
DACH1	OTMKNAGG	moderate	Biomarker	[236]
DAD1	OTUUNQBT	moderate	Biomarker	[237]
DCLRE1A	OT68PVSD	moderate	Genetic Variation	[238]
DIP2C	OTVNSS2T	moderate	Biomarker	[45]
EBNA1BP2	OTBRVMZH	moderate	Altered Expression	[49]
EGR4	OT4R3ECK	moderate	Biomarker	[239]
ETV4	OT8C98UZ	moderate	Biomarker	[240]
FBXW11	OT2A6RLR	moderate	Altered Expression	[241]
FIGNL1	OTKII63K	moderate	Altered Expression	[242]
FLII	OT7G9JG6	moderate	Biomarker	[243]
FMOD	OT9EJ5H8	moderate	Altered Expression	[244]
FOXL2	OTFRQUYL	moderate	Genetic Variation	[245]
GABBR1	OTU5A52J	moderate	Biomarker	[246]
GFI1B	OTRDW8YO	moderate	Biomarker	[247]
GHRH	OT94U6MO	moderate	Biomarker	[248]
GPM6A	OT8G13EG	moderate	Altered Expression	[86]
GPRC5A	OTPOCWR7	moderate	Biomarker	[249]
HBE1	OTJPKMX4	moderate	Biomarker	[250]
HCP5	OTV0YRI8	moderate	Biomarker	[236]
KCNH4	OTHJ8WTU	moderate	Biomarker	[251]
KIF21A	OT511XD9	moderate	Biomarker	[45]
KIF22	OTY6X6BL	moderate	Genetic Variation	[252]
KRT18	OTVLQFIP	moderate	Biomarker	[253]
LYRM9	OT1MILTK	moderate	Biomarker	[45]
MACF1	OTVIHD77	moderate	Genetic Variation	[66]
MKS1	OT83W5PB	moderate	Altered Expression	[191]
MPRIP	OT5FV5NS	moderate	Biomarker	[254]
NAPSA	OT6F8IAL	moderate	Biomarker	[255]
NDRG1	OTVO66BO	moderate	Biomarker	[256]
NLK	OT2LETFS	moderate	Biomarker	[257]
NNAT	OTNRLO7G	moderate	Biomarker	[258]
NUDT1	OTZSES3W	moderate	Genetic Variation	[238]
NUDT6	OTCS3NYZ	moderate	Biomarker	[133]
OBP2A	OTBIJ5TI	moderate	Genetic Variation	[252]
OPN3	OTON6BFU	moderate	Genetic Variation	[259]
OTUD5	OTMCR6JM	moderate	Biomarker	[260]
PCSK1N	OT7ZRW2F	moderate	Altered Expression	[261]
PIEZO1	OTBG1FU4	moderate	Altered Expression	[262]
PLSCR4	OT2AMYLY	moderate	Biomarker	[45]
PNN	OT0HXICH	moderate	Altered Expression	[263]
POU3F3	OT6BBXPD	moderate	Biomarker	[264]
POU3F4	OTKF5AF7	moderate	Biomarker	[264]
POU4F2	OT6SW5H0	moderate	Biomarker	[264]
POU4F3	OTILD0XS	moderate	Biomarker	[264]
PPP1R1B	OTSIJMQ9	moderate	Altered Expression	[265]
PROX1	OT68R6IO	moderate	Altered Expression	[266]
PSMD7	OT7PZZ4K	moderate	Altered Expression	[49]
PTPRA	OTZA82J1	moderate	Biomarker	[267]
PUM3	OTN1IPNS	moderate	Altered Expression	[261]
RAB38	OTU0NZU0	moderate	Genetic Variation	[66]
RAD51C	OTUD6SY5	moderate	Genetic Variation	[66]
RASSF8	OTXKGIB3	moderate	Biomarker	[45]
RBBP8	OTRHJ3GI	moderate	Altered Expression	[268]
RBM10	OTES2MES	moderate	Biomarker	[269]
RBP2	OTR8QG5V	moderate	Biomarker	[85]
RCAN1	OT1MVXC7	moderate	Biomarker	[270]
RHOH	OT1J9SEB	moderate	Genetic Variation	[271]
RIC1	OT3X4606	moderate	Altered Expression	[272]
RIMS2	OTQASWDH	moderate	Biomarker	[45]
RLF	OTCSPZVK	moderate	Biomarker	[45]
RPL17	OTTYMPS6	moderate	Biomarker	[273]
RUNX1T1	OT30DED5	moderate	Biomarker	[45]
S100A16	OT3ERKQI	moderate	Altered Expression	[274]
SATB2	OT2W80XC	moderate	Biomarker	[45]
SCGN	OTGD7SKH	moderate	Altered Expression	[275]
SDHC	OTC8G2MX	moderate	Altered Expression	[276]
SETDB1	OTWVUA1B	moderate	Biomarker	[277]
SFTA2	OTVRIUIV	moderate	Genetic Variation	[278]
SKA2	OTVYF4XT	moderate	Biomarker	[279]
SMUG1	OT2YIOCQ	moderate	Biomarker	[280]
SPATA2	OTOA45GL	moderate	Biomarker	[273]
SPTA1	OT1YMP65	moderate	Biomarker	[221]
SRPX	OT5B9LXS	moderate	Altered Expression	[281]
SYNM	OTOI8TRJ	moderate	Biomarker	[82]
TBX5	OT70PISV	moderate	Altered Expression	[241]
TCEAL9	OT4UHDB5	moderate	Altered Expression	[282]
TIMELESS	OTD8DCBJ	moderate	Altered Expression	[283]
TJP1	OTBDCUPK	moderate	Altered Expression	[284]
TRIB2	OTHSX3MX	moderate	Biomarker	[285]
TRIM46	OTFE7WZW	moderate	Biomarker	[286]
TSPAN12	OTF9I3CX	moderate	Biomarker	[287]
TSPAN33	OTH6C0WU	moderate	Altered Expression	[261]
A2ML1	OTWNUXIS	Strong	Biomarker	[288]
ACTN4	OTCNZAJ5	Strong	Genetic Variation	[289]
ASS1	OT4ZMG0Q	Strong	Altered Expression	[92]
ASXL3	OTNDJWEZ	Strong	Biomarker	[290]
AZIN2	OT8OB7CG	Strong	Biomarker	[291]
BCL10	OT47MCLI	Strong	Altered Expression	[292]
BCOR	OTG013AX	Strong	Genetic Variation	[293]
BLM	OTEJOAJX	Strong	Genetic Variation	[238]
C1QL1	OTNQ0G3E	Strong	Biomarker	[294]
CADM1	OTRWG9QS	Strong	Biomarker	[295]
CALM2	OTNYA92F	Strong	Biomarker	[296]
CAMKMT	OTLJBRUW	Strong	Biomarker	[296]
CBX4	OT4XVRRF	Strong	Biomarker	[297]
CDK2AP2	OTR99SJ8	Strong	Biomarker	[298]
CEACAM7	OTKFDTZY	Strong	Biomarker	[126]
CHD4	OTBDEHDP	Strong	Biomarker	[299]
CHGA	OTXYX5JH	Strong	Biomarker	[300]
CHPT1	OT4FJ0K3	Strong	Biomarker	[301]
CIC	OTFXCHNZ	Strong	Genetic Variation	[293]
COL11A2	OT3BQUBH	Strong	Biomarker	[128]
DAXX	OTX6O7PL	Strong	Biomarker	[302]
DERL2	OTI3TUUZ	Strong	Biomarker	[303]
DHDDS	OTVLYBUS	Strong	Biomarker	[301]
DHX9	OT5AAOQI	Strong	Altered Expression	[304]
DNER	OT2GH2E5	Strong	Genetic Variation	[305]
DYNLRB1	OTWVKOFB	Strong	Biomarker	[306]
ELAC2	OTY3BOF6	Strong	Biomarker	[297]
ENO2	OTRODL0T	Strong	Biomarker	[307]
EPB41L3	OTS6CHG2	Strong	Altered Expression	[308]
ERCC1	OTNPYQHI	Strong	Altered Expression	[309]
FLI1	OT0EV3LX	Strong	Biomarker	[310]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[311]
GADL1	OTJM4A0R	Strong	Biomarker	[291]
GAGE1	OT53E50E	Strong	Altered Expression	[151]
GFI1	OT9HB9H8	Strong	Altered Expression	[312]
GKN1	OT7ZYFQ9	Strong	Altered Expression	[193]
GLCE	OTPRSHX5	Strong	Altered Expression	[313]
GPRC5C	OT45AJT3	Strong	Altered Expression	[141]
GRP	OT8JDFNI	Strong	Biomarker	[314]
HDLBP	OTKDEEYX	Strong	Biomarker	[315]
HOXA1	OTMSOJ7D	Strong	Posttranslational Modification	[316]
HPR	OTXSC9UB	Strong	Biomarker	[317]
HSPA1A	OTKGIE76	Strong	Altered Expression	[318]
IL18R1	OT83XMPQ	Strong	Biomarker	[134]
ING5	OTRNNSFM	Strong	Altered Expression	[319]
IPO9	OT1DGLQE	Strong	Biomarker	[299]
KLHL1	OTAX6SAD	Strong	Altered Expression	[320]
KRIT1	OT58AP1I	Strong	Biomarker	[296]
LAMTOR2	OTHEDISB	Strong	Biomarker	[298]
LMO1	OTB59SKB	Strong	Biomarker	[321]
MAD2L1	OTXNGZCG	Strong	Biomarker	[322]
MAGED4B	OTO37U7W	Strong	Altered Expression	[151]
MAML3	OTZFV53Z	Strong	Biomarker	[164]
MCC	OTQVI1EM	Strong	Biomarker	[323]
MGA	OTTLB216	Strong	Altered Expression	[205]
MVP	OTJGHJRB	Strong	Biomarker	[267]
MXI1	OTUQ9E0D	Strong	Biomarker	[324]
MZB1	OT071TET	Strong	Altered Expression	[325]
NEUROD1	OTZQ7QJ2	Strong	Biomarker	[230]
NFIB	OTX94PD0	Strong	Biomarker	[326]
NMB	OT4NLN6H	Strong	Altered Expression	[306]
NOCT	OTVSYP2D	Strong	Genetic Variation	[327]
NOLC1	OTKDZU0D	Strong	Biomarker	[328]
NPTXR	OTQJEOIH	Strong	Biomarker	[329]
NUTM1	OTONYC08	Strong	Altered Expression	[330]
OTUD4	OT7U62SW	Strong	Posttranslational Modification	[331]
PAX3	OTN5PJZV	Strong	Altered Expression	[332]
PDYN	OTEJ6430	Strong	Altered Expression	[333]
PENK	OT8P3HMP	Strong	Altered Expression	[334]
PFKFB4	OTQYEXL2	Strong	Biomarker	[67]
PIGR	OT6GLSUL	Strong	Biomarker	[335]
PIK3IP1	OTWE5G4T	Strong	Altered Expression	[209]
PIP	OTH719AH	Strong	Biomarker	[336]
PMAIP1	OTXEE550	Strong	Altered Expression	[337]
POLD4	OTG578YH	Strong	Altered Expression	[338]
POU2F3	OTIOOJWD	Strong	Altered Expression	[339]
POU3F2	OT30NFOC	Strong	Altered Expression	[340]
PRIMA1	OT9ITT3P	Strong	Biomarker	[149]
PSG2	OT2EIXAI	Strong	Biomarker	[126]
PTH2	OTV5C5VT	Strong	Altered Expression	[341]
PXN	OTVMMUOF	Strong	Biomarker	[342]
RAB3GAP1	OT4DQ8F2	Strong	Biomarker	[328]
RALGAPB	OTY8CGA3	Strong	Biomarker	[288]
RBL2	OTBQSOE6	Strong	Biomarker	[328]
RBM5	OTCBWHHV	Strong	Biomarker	[269]
RGCC	OTYJMLWM	Strong	Genetic Variation	[343]
RIPK3	OTL1D484	Strong	Biomarker	[254]
RPP14	OT4OYFSK	Strong	Biomarker	[298]
RTN1	OTCX1SMK	Strong	Biomarker	[344]
SAA2	OTYAVJWG	Strong	Biomarker	[345]
SCGB3A1	OTIR98RB	Strong	Posttranslational Modification	[331]
SCNN1A	OTE2KVZV	Strong	Altered Expression	[346]
SEMA3B	OTCZCPMS	Strong	Biomarker	[347]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[348]
SERPINA5	OTTZXPGD	Strong	Biomarker	[349]
SET	OTGYYQJO	Strong	Biomarker	[277]
SF3B6	OTPRKS6S	Strong	Biomarker	[298]
SMARCC1	OTUOMBE7	Strong	Genetic Variation	[350]
SOX1	OTVI1RAR	Strong	Biomarker	[351]
SOX11	OT4LG7LA	Strong	Altered Expression	[352]
SOX21	OTNT50CC	Strong	Altered Expression	[353]
SOX3	OT1CRCOB	Strong	Altered Expression	[353]
SPECC1	OTPEML48	Strong	Biomarker	[344]
SRRM4	OTALUISN	Strong	Biomarker	[354]
SRSF5	OTC5WP98	Strong	Biomarker	[355]
SYCE1L	OTXU44F3	Strong	Altered Expression	[320]
SYP	OTFJKMO4	Strong	Biomarker	[300]
TAP2	OTWSYFI7	Strong	Altered Expression	[356]
TAPBP	OTL81AVZ	Strong	Biomarker	[357]
TLE1	OT50MRZ1	Strong	Altered Expression	[358]
TMPRSS13	OTMAOAP3	Strong	Altered Expression	[209]
TTF1	OT4K90WD	Strong	Biomarker	[230]
ELAVL2	OT6EJ8MQ	Definitive	Biomarker	[45]
ERG	OTOTX9VU	Definitive	Genetic Variation	[184]
HMGB3	OTCJ2EZY	Definitive	Genetic Variation	[359]
HYAL1	OT2SJN0X	Definitive	Altered Expression	[203]
MARCKSL1	OT13J2FM	Definitive	Biomarker	[360]
MTHFD1	OTMKHVWC	Definitive	Biomarker	[361]
MTHFS	OTZ39JNR	Definitive	Biomarker	[361]
RASGRF2	OT67DAGF	Definitive	Posttranslational Modification	[362]
RNASE3	OTVE2XD1	Definitive	Biomarker	[363]
SCG5	OTXSJMT1	Definitive	Biomarker	[202]
SEZ6L	OT5Z9CUA	Definitive	Altered Expression	[364]
SMARCA1	OT0Y6PTU	Definitive	Altered Expression	[365]
SMARCA2	OTSGJ8SV	Definitive	Biomarker	[60]
TRDMT1	OTAYQ8ZF	Definitive	Genetic Variation	[361]
------------------------------------------------------------------------------------


⏷ Show the Full List of 275 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Carboplatin FDA Label
4	Cisplatin FDA Label
5	Doxorubicin FDA Label
6	Etoposide FDA Label
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8	Pemetrexed FDA Label
9	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
10	ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
12	ClinicalTrials.gov (NCT01535560) Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa. U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT00547651) AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy. U.S. National Institutes of Health.
14	ClinicalTrials.gov (NCT00676507) Phase III Lucanix Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy. U.S. National Institutes of Health.
15	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
17	ClinicalTrials.gov (NCT03699956) RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM). U.S. National Institutes of Health.
18	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19	ClinicalTrials.gov (NCT03366675) AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT03428607) Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health.
22	ClinicalTrials.gov (NCT03879798) DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
23	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
24	ClinicalTrials.gov (NCT01017601) Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer. U.S. National Institutes of Health.
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013510)
26	ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT05060016) A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301). U.S.National Institutes of Health.
28	ClinicalTrials.gov (NCT04210037) Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer. U.S. National Institutes of Health.
29	ClinicalTrials.gov (NCT04101357) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411. U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT04471727) Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy. U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT02030184) Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas. U.S. National Institutes of Health.
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038447)
33	ClinicalTrials.gov (NCT03639194) A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer. U.S. National Institutes of Health.
34	ClinicalTrials.gov (NCT03392064) A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
35	ClinicalTrials.gov (NCT02034123) Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT03460977) PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma. U.S. National Institutes of Health.
37	ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
38	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7874).
39	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
40	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
41	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12.
42	Inhibitory effects of XAV939 on the proliferation of small-cell lung cancer H446 cells and Wnt/-catenin signaling pathway in vitro.Oncol Lett. 2018 Aug;16(2):1953-1958. doi: 10.3892/ol.2018.8790. Epub 2018 May 24.
43	Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.PLoS One. 2018 Jul 26;13(7):e0200633. doi: 10.1371/journal.pone.0200633. eCollection 2018.
44	Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells.Oncogene. 2003 Aug 28;22(36):5636-45. doi: 10.1038/sj.onc.1206790.
45	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.
46	Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.J Pathol. 2000 Jun;191(2):193-201. doi: 10.1002/(SICI)1096-9896(200006)191:2<193::AID-PATH602>3.0.CO;2-4.
47	Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.Sci Signal. 2019 Feb 5;12(567):eaau2922. doi: 10.1126/scisignal.aau2922.
48	Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas.Biochem Biophys Res Commun. 2000 Aug 28;275(2):440-5. doi: 10.1006/bbrc.2000.3331.
49	P40 expression in small cell lung cancer: The presence of p40-positive cells does not always indicate squamous differentiation.Thorac Cancer. 2019 May;10(5):1188-1192. doi: 10.1111/1759-7714.13062. Epub 2019 Apr 7.
50	MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.World J Surg Oncol. 2018 Jun 18;16(1):110. doi: 10.1186/s12957-018-1413-7.
51	Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer.Onco Targets Ther. 2019 Nov 21;12:10043-10055. doi: 10.2147/OTT.S216362. eCollection 2019.
52	Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling.Cancer Res. 2002 Aug 15;62(16):4623-9.
53	Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.BMC Cancer. 2014 Mar 14;14:185. doi: 10.1186/1471-2407-14-185.
54	Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.Cancer Lett. 2018 Nov 1;436:1-9. doi: 10.1016/j.canlet.2018.08.007. Epub 2018 Aug 14.
55	Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer.J Cell Mol Med. 2019 Mar;23(3):2077-2082. doi: 10.1111/jcmm.14116. Epub 2019 Jan 11.
56	Clinical relevance and accuracy of p63 and TTF-1 for better approach of small cell lung carcinoma versus poorly differentiated nonkeratinizing squamous cell carcinoma.Rom J Morphol Embryol. 2019;60(1):139-143.
57	Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer.Mol Cancer Res. 2018 Jan;16(1):47-57. doi: 10.1158/1541-7786.MCR-16-0341. Epub 2017 Oct 9.
58	Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.J Proteome Res. 2017 Dec 1;16(12):4495-4505. doi: 10.1021/acs.jproteome.7b00484. Epub 2017 Oct 12.
59	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.Nat Genet. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2.
60	The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.Nat Genet. 2019 Apr;51(4):618-626. doi: 10.1038/s41588-019-0363-5. Epub 2019 Mar 11.
61	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.J Neuroimmunol. 2019 Jan 15;326:14-18. doi: 10.1016/j.jneuroim.2018.11.003. Epub 2018 Nov 8.
62	NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer.Oncol Rep. 2014 Dec;32(6):2589-95. doi: 10.3892/or.2014.3494. Epub 2014 Sep 17.
63	The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.Oncol Rep. 2005 Aug;14(2):421-4.
64	Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer.Yonsei Med J. 2016 May;57(3):549-56. doi: 10.3349/ymj.2016.57.3.549.
65	Clinical and Prognostic Significance of ANCCA in Squamous Cell Lung Carcinoma Patients.Arch Med Res. 2016 Feb;47(2):89-95. doi: 10.1016/j.arcmed.2016.04.001. Epub 2016 Apr 27.
66	Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.Clin Cancer Res. 2018 Apr 1;24(7):1691-1704. doi: 10.1158/1078-0432.CCR-17-0252. Epub 2018 Jan 19.
67	Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.Clin Cancer Res. 2018 Feb 15;24(4):950-962. doi: 10.1158/1078-0432.CCR-17-1475. Epub 2017 Dec 5.
68	BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis.J Neuroimmunol. 2005 Dec 30;170(1-2):186-90. doi: 10.1016/j.jneuroim.2005.08.011. Epub 2005 Sep 13.
69	Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1.J Proteome Res. 2011 Jan 7;10(1):269-76. doi: 10.1021/pr100714b. Epub 2010 Dec 2.
70	MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer.Oncotarget. 2016 Apr 19;7(16):22632-8. doi: 10.18632/oncotarget.8134.
71	MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2.Int J Clin Exp Pathol. 2014 Oct 15;7(11):7726-34. eCollection 2014.
72	Endosialin: a novel malignant cell therapeutic target for neuroblastoma.Int J Oncol. 2011 Oct;39(4):841-51. doi: 10.3892/ijo.2011.1091. Epub 2011 Jun 20.
73	Vasculogenic mimicry in small cell lung cancer.Nat Commun. 2016 Nov 9;7:13322. doi: 10.1038/ncomms13322.
74	Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro.Virol J. 2017 Oct 3;14(1):190. doi: 10.1186/s12985-017-0852-z.
75	Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial-mesenchymal transition.Sci Rep. 2019 Aug 19;9(1):12030. doi: 10.1038/s41598-019-48476-8.
76	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.Ann Oncol. 1997 Jan;8(1):49-56. doi: 10.1023/a:1008232329498.
77	Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10. doi: 10.1016/j.bbrc.2005.08.268. Epub 2005 Sep 15.
78	Identification of DHODH as a therapeutic target in small cell lung cancer.Sci Transl Med. 2019 Nov 6;11(517):eaaw7852. doi: 10.1126/scitranslmed.aaw7852.
79	An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene.Lung Cancer. 2013 Sep;81(3):487-490. doi: 10.1016/j.lungcan.2013.05.022. Epub 2013 Jun 17.
80	Cellular models of drug- and radiation-resistant small cell lung cancer.Anticancer Res. 2004 Mar-Apr;24(2A):465-71.
81	A long non-coding RNA HOTTIP expression is associated with disease progression and predicts outcome in small cell lung cancer patients.Mol Cancer. 2017 Oct 17;16(1):162. doi: 10.1186/s12943-017-0729-1.
82	Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor.J Thorac Dis. 2018 Dec;10(12):6912-6920. doi: 10.21037/jtd.2018.11.115.
83	Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.Clin Cancer Res. 2009 Apr 1;15(7):2222-30. doi: 10.1158/1078-0432.CCR-08-2443. Epub 2009 Mar 10.
84	KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.Cancer Res. 2015 Sep 15;75(18):3936-45. doi: 10.1158/0008-5472.CAN-14-3702. Epub 2015 Jul 24.
85	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.Genes Dev. 2019 Dec 1;33(23-24):1718-1738. doi: 10.1101/gad.328336.119. Epub 2019 Nov 14.
86	miR-22 enhances the radiosensitivity of small-cell lung cancer by targeting the WRNIP1.J Cell Biochem. 2019 Oct;120(10):17650-17661. doi: 10.1002/jcb.29032. Epub 2019 Jun 12.
87	Lysosome-associated protein transmembrane-4-35 is a novel independent prognostic factor in small cell lung cancer.Tumour Biol. 2015 Sep;36(10):7493-9. doi: 10.1007/s13277-015-3467-2. Epub 2015 Apr 25.
88	Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer. 2015 Mar 12;14:59.
89	Trends in stereotactic body radiation therapy for stage I small cell lung cancer.Lung Cancer. 2017 Jan;103:11-16. doi: 10.1016/j.lungcan.2016.11.009. Epub 2016 Nov 16.
90	Role of miR-579-3p in the development of squamous cell lung carcinoma and the regulatory mechanisms.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9464-9470. doi: 10.26355/eurrev_201911_19440.
91	Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.Oncotarget. 2017 Sep 12;8(44):77846-77859. doi: 10.18632/oncotarget.20840. eCollection 2017 Sep 29.
92	Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.Cancer Sci. 2018 Nov;109(11):3471-3482. doi: 10.1111/cas.13782. Epub 2018 Oct 6.
93	The effect of down regulation of calcineurin A by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.Clin Exp Metastasis. 2011 Dec;28(8):765-78. doi: 10.1007/s10585-011-9408-6. Epub 2011 Jul 23.
94	PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.BMC Cancer. 2012 Nov 21;12:537. doi: 10.1186/1471-2407-12-537.
95	Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.J Thorac Oncol. 2008 Jun;3(6):583-9. doi: 10.1097/JTO.0b013e3181734f24.
96	CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.
97	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.Oncol Rep. 2011 Oct;26(4):931-7. doi: 10.3892/or.2011.1384. Epub 2011 Jul 11.
98	Whole-genome analysis of a patient with early-stage small-cell lung cancer.Pharmacogenomics J. 2014 Dec;14(6):503-8. doi: 10.1038/tpj.2014.17. Epub 2014 Apr 8.
99	Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy.Cancer Lett. 2015 Jan 28;356(2 Pt B):517-24. doi: 10.1016/j.canlet.2014.09.025. Epub 2014 Oct 6.
100	Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer.Nanoscale. 2019 Aug 1;11(30):14400-14409. doi: 10.1039/c9nr04371c.
101	Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.J Med Chem. 2019 Mar 14;62(5):2708-2719. doi: 10.1021/acs.jmedchem.8b02036. Epub 2019 Feb 28.
102	Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.J Clin Endocrinol Metab. 2015 Mar;100(3):831-40. doi: 10.1210/jc.2014-2699. Epub 2014 Dec 12.
103	Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells.Biochem Pharmacol. 2013 Feb 1;85(3):426-38. doi: 10.1016/j.bcp.2012.11.019. Epub 2012 Dec 5.
104	Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition.Br J Cancer. 2005 Feb 14;92(3):522-31. doi: 10.1038/sj.bjc.6602366.
105	A Regulatory MDM4 Genetic Variant Locating in the Binding Sequence of Multiple MicroRNAs Contributes to Susceptibility of Small Cell Lung Cancer.PLoS One. 2015 Aug 14;10(8):e0135647. doi: 10.1371/journal.pone.0135647. eCollection 2015.
106	Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer.PLoS One. 2013 May 7;8(5):e63404. doi: 10.1371/journal.pone.0063404. Print 2013.
107	Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.Int J Oncol. 2003 Jul;23(1):173-9.
108	Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model.Anticancer Res. 2005 Jan-Feb;25(1A):255-61.
109	Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.Lab Invest. 2019 Nov;99(11):1622-1635. doi: 10.1038/s41374-019-0277-y. Epub 2019 Jun 23.
110	PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.Lung Cancer. 2020 Jan;139:146-150. doi: 10.1016/j.lungcan.2019.11.002. Epub 2019 Nov 6.
111	PCR-based RFLP analysis allows genotyping of the short arm of chromosome 3 in small biopsies from patients with lung cancer.Genomics. 1992 Feb;12(2):221-8. doi: 10.1016/0888-7543(92)90369-4.
112	Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.
113	The productions of atrial natriuretic peptide and arginine vasopressin in small cell lung cancer with brain metastases and their associations with hyponatremia.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4104-4112.
114	Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung.Lung Cancer. 2005 Nov;50(2):177-88. doi: 10.1016/j.lungcan.2005.05.027. Epub 2005 Jul 25.
115	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
116	Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.Clin Cancer Res. 2012 Feb 1;18(3):783-95. doi: 10.1158/1078-0432.CCR-11-1166. Epub 2011 Dec 15.
117	Hierarchical clustering of lung cancer cell lines using DNA methylation markers.Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):291-7.
118	Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.Oncogene. 2002 Dec 5;21(55):8510-4. doi: 10.1038/sj.onc.1205941.
119	NNK reduction pathway gene polymorphisms and risk of lung cancer.Mol Carcinog. 2015 Jun;54 Suppl 1(Suppl 1):E94-E102. doi: 10.1002/mc.22187. Epub 2014 Jun 29.
120	CCKA and CCKB receptors are expressed in small cell lung cancer lines and mediate Ca2+ mobilization and clonal growth.Cancer Res. 1993 Nov 1;53(21):5208-13.
121	Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.Oncologist. 2019 Feb;24(Suppl 1):S21-S30. doi: 10.1634/theoncologist.2019-IO-S1-s02.
122	CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice.Oncol Res. 2005;15(7-8):365-72. doi: 10.3727/096504005776449699.
123	Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Sci Rep. 2017 Nov 14;7(1):15511. doi: 10.1038/s41598-017-15840-5.
124	Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database. Pathol Res Pract. 2018 Nov;214(11):1854-1867.
125	Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.Cancer Cell. 2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019.
126	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0.
127	Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.J Cancer Res Clin Oncol. 1987;113(3):253-9. doi: 10.1007/BF00396382.
128	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.
129	MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther. 2008 May;7(5):1150-5.
130	Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.Am J Hematol. 2004 Jul;76(3):214-9. doi: 10.1002/ajh.20079.
131	DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.Lung Cancer. 2003 May;40(2):157-64. doi: 10.1016/s0169-5002(03)00026-6.
132	Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.Cancer Gene Ther. 2020 May;27(5):294-300. doi: 10.1038/s41417-019-0099-5. Epub 2019 May 9.
133	Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells.Acta Biochim Biophys Sin (Shanghai). 2008 Apr;40(4):297-303. doi: 10.1111/j.1745-7270.2008.00401.x.
134	Chronic Obstructive Pulmonary Disease Molecular Subtyping and Pathway Deviation-Based Candidate Gene Identification.Cell J. 2018 Oct;20(3):326-332. doi: 10.22074/cellj.2018.5412. Epub 2018 May 15.
135	Genomic alterations in neuroendocrine cancers of the ovary.J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.
136	Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.Thorac Cancer. 2019 Apr;10(4):839-847. doi: 10.1111/1759-7714.13011. Epub 2019 Feb 21.
137	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.Clin Lung Cancer. 2019 Jan;20(1):e39-e51. doi: 10.1016/j.cllc.2018.09.001. Epub 2018 Sep 7.
138	The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.Cancer Invest. 2011 Dec;29(10):683-91. doi: 10.3109/07357907.2011.626475.
139	Plasmin: its role in the extracellular processing of progalanin in tumor tissue.Protein Pept Lett. 2011 Dec;18(12):1204-11. doi: 10.2174/092986611797642751.
140	Phorbol esters regulate preprogastrin-releasing peptide messenger RNA in small cell lung cancer cells.Cell Growth Differ. 1993 Sep;4(9):723-9.
141	Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression.Mol Cancer Res. 2012 Oct;10(10):1343-58. doi: 10.1158/1541-7786.MCR-12-0139. Epub 2012 Aug 21.
142	Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11)-induced growth inhibition.Br J Cancer. 2003 Jun 2;88(11):1808-16. doi: 10.1038/sj.bjc.6600957.
143	Real-time RT-PCR analysis of human histidine decarboxylase, a new marker for several types of leukemia and cancer.Oncol Rep. 2006 Jan;15(1):193-7.
144	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.Clin Cancer Res. 2019 Jan 1;25(1):346-357. doi: 10.1158/1078-0432.CCR-18-1129. Epub 2018 Sep 26.
145	TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression.Hum Pathol. 2007 Feb;38(2):293-8. doi: 10.1016/j.humpath.2006.08.005. Epub 2006 Nov 13.
146	Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
147	Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.Lung Cancer. 2014 Dec;86(3):318-23. doi: 10.1016/j.lungcan.2014.09.018. Epub 2014 Oct 12.
148	Lineage relationship between prostate adenocarcinoma and small cell carcinoma.BMC Cancer. 2019 May 30;19(1):518. doi: 10.1186/s12885-019-5680-7.
149	PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.Clin Cancer Res. 2011 May 1;17(9):2830-41. doi: 10.1158/1078-0432.CCR-10-3168. Epub 2011 Mar 17.
150	Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection.Tumour Biol. 2016 Apr;37(4):4393-8. doi: 10.1007/s13277-015-4302-5. Epub 2015 Oct 24.
151	IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer.Gene Ther. 1997 Oct;4(10):1029-35. doi: 10.1038/sj.gt.3300489.
152	Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer.Ann Thorac Surg. 2017 Jun;103(6):1767-1772. doi: 10.1016/j.athoracsur.2017.01.043. Epub 2017 Apr 25.
153	Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.Mol Cancer Res. 2019 Jan;17(1):42-53. doi: 10.1158/1541-7786.MCR-18-0650. Epub 2018 Sep 10.
154	The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes.J Hum Genet. 2017 Jul;62(7):671-678. doi: 10.1038/jhg.2017.27. Epub 2017 Mar 9.
155	Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens.Hum Pathol. 2019 Mar;85:58-64. doi: 10.1016/j.humpath.2018.10.016. Epub 2018 Oct 30.
156	Protease inhibitors suppress in vitro growth of human small cell lung cancer.Peptides. 1993 Sep-Oct;14(5):1021-8. doi: 10.1016/0196-9781(93)90081-q.
157	An immunohistochemical and molecular genetic analysis of KIT and PDGFRA in small cell lung carcinoma in Japanese.Int J Clin Exp Pathol. 2012;5(4):331-8. Epub 2012 Apr 16.
158	Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.Cancer Sci. 2013 Jan;104(1):78-84. doi: 10.1111/cas.12045. Epub 2012 Nov 24.
159	Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.Mol Biol Rep. 2018 Jun;45(3):253-261. doi: 10.1007/s11033-018-4158-z. Epub 2018 Feb 3.
160	Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines.Immunol Lett. 1996 May;50(3):149-54. doi: 10.1016/0165-2478(96)02531-x.
161	Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.Oncogene. 2008 Mar 13;27(12):1737-48. doi: 10.1038/sj.onc.1210819. Epub 2007 Oct 1.
162	Determinants of differential doxorubicin sensitivity between SCLC and NSCLC.FEBS Lett. 2006 Apr 17;580(9):2258-64. doi: 10.1016/j.febslet.2006.03.038. Epub 2006 Mar 24.
163	Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage.J Oncol. 2019 May 2;2019:5437390. doi: 10.1155/2019/5437390. eCollection 2019.
164	RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer. Anticancer Res. 2018 Aug;38(8):4543-4547.
165	Establishment of a novel small cell lung carcinoma cell line with specific recoverin expression from a patient with cancer-associated retinopathy.Lung Cancer. 2007 Jun;56(3):319-26. doi: 10.1016/j.lungcan.2007.01.030. Epub 2007 Mar 19.
166	Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.Hum Pathol. 2019 Nov;93:74-80. doi: 10.1016/j.humpath.2019.08.018. Epub 2019 Aug 24.
167	Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer.Oncogene. 2001 Jul 5;20(30):3929-36. doi: 10.1038/sj.onc.1204536.
168	Pathobiology of Notch2 in lung cancer.Pathology. 2017 Aug;49(5):486-493. doi: 10.1016/j.pathol.2017.05.005. Epub 2017 Jun 27.
169	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer.Expert Opin Biol Ther. 2019 Jun;19(6):509-515. doi: 10.1080/14712598.2019.1610380. Epub 2019 Apr 29.
170	CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target.Int J Cancer. 2013 Apr 15;132(8):1761-70. doi: 10.1002/ijc.27873. Epub 2012 Oct 29.
171	Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction.Neoplasma. 2017;64(6):869-879. doi: 10.4149/neo_2017_608.
172	Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.Cancer Res. 2005 Sep 1;65(17):7926-33. doi: 10.1158/0008-5472.CAN-04-3977.
173	In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer.Am J Respir Cell Mol Biol. 2003 Apr;28(4):428-35. doi: 10.1165/rcmb.2002-0114OC.
174	Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers.Am J Hum Genet. 1989 Feb;44(2):282-7.
175	Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer.Proc Natl Acad Sci U S A. 1988 Dec;85(23):9258-62. doi: 10.1073/pnas.85.23.9258.
176	Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.Jpn J Cancer Res. 1998 Aug;89(8):855-61. doi: 10.1111/j.1349-7006.1998.tb00640.x.
177	TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.Oncogene. 1998 Sep 3;17(9):1141-8. doi: 10.1038/sj.onc.1202029.
178	Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis.Int J Biol Sci. 2018 Jul 13;14(10):1221-1231. doi: 10.7150/ijbs.25488. eCollection 2018.
179	Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.J Natl Cancer Inst. 2018 Sep 1;110(9):967-974. doi: 10.1093/jnci/djy002.
180	Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.Invest New Drugs. 2020 Aug;38(4):946-955. doi: 10.1007/s10637-019-00847-8. Epub 2019 Aug 24.
181	Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.Thorac Cancer. 2020 Jan;11(1):19-28. doi: 10.1111/1759-7714.13212. Epub 2019 Nov 5.
182	Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer.BMC Cancer. 2017 Nov 7;17(1):719. doi: 10.1186/s12885-017-3701-y.
183	Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.
184	Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.Mol Carcinog. 2015 Sep;54(9):900-7. doi: 10.1002/mc.22162. Epub 2014 Apr 29.
185	Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.Br J Cancer. 2004 Jun 14;90(12):2411-7. doi: 10.1038/sj.bjc.6601863.
186	Cytotoxic effects of pyrrolidine dithiocarbamate in small-cell lung cancer cells, alone and in combination with cisplatin. Int J Oncol. 2014 Oct;45(4):1749-59. doi: 10.3892/ijo.2014.2564. Epub 2014 Jul 28.
187	MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther. 2007 Jan;6(1):122-7.
188	Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.Br J Cancer. 2006 Jun 19;94(12):1927-35. doi: 10.1038/sj.bjc.6603167. Epub 2006 May 16.
189	Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.Int J Mol Med. 2015 Feb;35(2):425-32. doi: 10.3892/ijmm.2014.2033. Epub 2014 Dec 10.
190	Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R/IRS1/PI3K/AKT/Nrf2/FLIP/Caspase-3 signaling pathway in small cell lung cancer.Oncol Lett. 2018 Nov;16(5):6445-6457. doi: 10.3892/ol.2018.9486. Epub 2018 Sep 24.
191	miR-541 suppresses proliferation and invasion of squamous cell lung carcinoma cell lines via directly targeting high-mobility group AT-hook 2.Cancer Med. 2018 Jun;7(6):2581-2591. doi: 10.1002/cam4.1491. Epub 2018 Apr 16.
192	Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.J Steroid Biochem Mol Biol. 1998 Nov;67(4):341-6. doi: 10.1016/s0960-0760(98)00125-3.
193	Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer.Cell Biol Toxicol. 2016 Oct;32(5):419-35. doi: 10.1007/s10565-016-9343-z. Epub 2016 Jun 15.
194	Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors.Int J Biol Markers. 2007 Apr-Jun;22(2):114-23. doi: 10.1177/172460080702200205.
195	The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.Cancer Biomark. 2019;24(1):51-59. doi: 10.3233/CBM-181692.
196	Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.Oncotarget. 2017 Nov 25;8(66):110273-110288. doi: 10.18632/oncotarget.22681. eCollection 2017 Dec 15.
197	CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.Theranostics. 2019 Jul 9;9(16):4717-4729. doi: 10.7150/thno.33680. eCollection 2019.
198	Corin-mediated processing of pro-atrial natriuretic peptide in human small cell lung cancer cells.Cancer Res. 2003 Dec 1;63(23):8318-22.
199	Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.Cancer Res. 1999 Apr 15;59(8):1846-51.
200	Antibody recognition and RNA binding of a neuronal nuclear autoantigen associated with paraneoplastic neurological syndromes and small cell lung carcinoma.J Neuroimmunol. 1999 Jan 1;93(1-2):37-44. doi: 10.1016/s0165-5728(98)00184-2.
201	MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2.Bioengineered. 2019 Dec;10(1):1-12. doi: 10.1080/21655979.2019.1586056.
202	Key genes in lung cancer translational research: a meta-analysis.Pathobiology. 2010;77(2):53-63. doi: 10.1159/000278292. Epub 2010 Mar 22.
203	Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines.Oncol Rep. 2003 May-Jun;10(3):609-16.
204	KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer.Mol Cell Biochem. 2016 Nov;422(1-2):61-74. doi: 10.1007/s11010-016-2806-y. Epub 2016 Sep 19.
205	MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.
206	Taking SCLC on a Bad LSD(1) Trip One NOTCH Further.Trends Mol Med. 2019 Apr;25(4):261-264. doi: 10.1016/j.molmed.2019.02.009. Epub 2019 Mar 6.
207	Loss of imprinting of PEG1/MEST in lung cancer cell lines.Oncol Rep. 2004 Dec;12(6):1273-8.
208	Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery.Lung Cancer. 2011 Nov;74(2):332-7. doi: 10.1016/j.lungcan.2011.03.004. Epub 2011 May 6.
209	Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival.J Clin Invest. 1997 Jun 15;99(12):2979-91. doi: 10.1172/JCI119493.
210	Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.Oncotarget. 2017 Jul 25;8(30):48983-48995. doi: 10.18632/oncotarget.16904.
211	MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer.Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12269-74. doi: 10.1073/pnas.192445899. Epub 2002 Sep 3.
212	Detection of tumor specific gene expression in bone marrow and peripheral blood from patients with small cell lung carcinoma.Cancer. 2003 Feb 15;97(4):1057-62. doi: 10.1002/cncr.11108.
213	PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.
214	Neuropeptide G Protein-Coupled Receptors as Oncotargets.Front Endocrinol (Lausanne). 2018 Jun 29;9:345. doi: 10.3389/fendo.2018.00345. eCollection 2018.
215	Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation.EMBO J. 2002 Oct 1;21(19):5097-108. doi: 10.1093/emboj/cdf512.
216	Liprin-4 as a New Therapeutic Target for SCLC as an Upstream Mediator of HIF1.Anticancer Res. 2019 Mar;39(3):1179-1184. doi: 10.21873/anticanres.13227.
217	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.Hum Pathol. 2018 Sep;79:57-65. doi: 10.1016/j.humpath.2018.05.005. Epub 2018 May 12.
218	Production and characterization of monoclonal antibodies against the DNA binding domain of the RE1-silencing transcription factor.J Biochem. 2019 Nov 1;166(5):393-402. doi: 10.1093/jb/mvz046.
219	Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.Respir Med. 2005 Sep;99(9):1164-74. doi: 10.1016/j.rmed.2005.02.009.
220	Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.Expert Rev Anticancer Ther. 2019 Jun;19(6):461-471. doi: 10.1080/14737140.2019.1624530. Epub 2019 May 31.
221	Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing.Carcinogenesis. 2015 Jun;36(6):616-21. doi: 10.1093/carcin/bgv026. Epub 2015 Apr 11.
222	Comprehensive genomic profiles of small cell lung cancer.Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.
223	Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.Med Sci Monit. 2019 Mar 26;25:2228-2237. doi: 10.12659/MSM.913091.
224	Inflammatory flaccid myelitis in a patient with both anti-CRMP-5 IgG and CNS HIV escape.BMJ Case Rep. 2019 May 21;12(5):e228378. doi: 10.1136/bcr-2018-228378.
225	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.Cancer Res. 2005 Jul 1;65(13):5561-70. doi: 10.1158/0008-5472.CAN-04-4603.
226	A small interfering ABCE1-targeting RNA inhibits the proliferation and invasiveness of small cell lung cancer.Int J Mol Med. 2010 May;25(5):687-93.
227	Expression of ADAM12 is regulated by E2F1 in small cell lung cancer.Oncol Rep. 2015 Dec;34(6):3231-7. doi: 10.3892/or.2015.4317.
228	BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas.Histopathology. 2014 Mar;64(4):547-56. doi: 10.1111/his.12278. Epub 2013 Nov 25.
229	PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.Sci Rep. 2013;3:1911. doi: 10.1038/srep01911.
230	Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.Mol Oncol. 2020 Feb;14(2):277-293. doi: 10.1002/1878-0261.12608. Epub 2019 Dec 15.
231	Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer.Tumour Biol. 2016 Oct;37(10):13185-13203. doi: 10.1007/s13277-016-5178-8. Epub 2016 Jul 25.
232	Variant Ciz1 is a circulating biomarker for early-stage lung cancer.Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3128-35. doi: 10.1073/pnas.1210107109. Epub 2012 Oct 16.
233	Nephrotic Syndrome in Small Cell Lung Cancer and Induction of C-Mip in Podocytes.Am J Kidney Dis. 2017 Mar;69(3):477-480. doi: 10.1053/j.ajkd.2016.09.026. Epub 2017 Jan 4.
234	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.Respir Res. 2019 Nov 7;20(1):248. doi: 10.1186/s12931-019-1205-9.
235	Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin 1.J Clin Invest. 2019 Mar 1;129(3):972-987. doi: 10.1172/JCI122779. Epub 2019 Jan 28.
236	Identification of candidate genes or microRNAs associated with the lymph node metastasis of SCLC.Cancer Cell Int. 2018 Oct 19;18:161. doi: 10.1186/s12935-018-0653-5. eCollection 2018.
237	Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.Oncogene. 2006 Jan 5;25(1):130-8. doi: 10.1038/sj.onc.1208997.
238	Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk.Carcinogenesis. 2006 Dec;27(12):2448-54. doi: 10.1093/carcin/bgl095. Epub 2006 Jun 14.
239	Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes.PLoS One. 2014 Nov 20;9(11):e113606. doi: 10.1371/journal.pone.0113606. eCollection 2014.
240	Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics.Mod Pathol. 2016 Nov;29(11):1324-1334. doi: 10.1038/modpathol.2016.140. Epub 2016 Jul 22.
241	Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.
242	FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide.Oncol Rep. 2017 Apr;37(4):1935-1942. doi: 10.3892/or.2017.5483. Epub 2017 Mar 1.
243	MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.Am J Cancer Res. 2019 Sep 1;9(9):1938-1956. eCollection 2019.
244	Tumor angiogenesis of SCLC inhibited by decreased expression of FMOD via downregulating angiogenic factors of endothelial cells.Biomed Pharmacother. 2017 Mar;87:539-547. doi: 10.1016/j.biopha.2016.12.110. Epub 2017 Jan 9.
245	Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance.Histopathology. 2016 Dec;69(6):903-913. doi: 10.1111/his.13058. Epub 2016 Oct 3.
246	Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.Lancet Neurol. 2010 Jan;9(1):67-76. doi: 10.1016/S1474-4422(09)70324-2. Epub 2009 Dec 2.
247	LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.Cancer Res. 2017 Sep 1;77(17):4652-4662. doi: 10.1158/0008-5472.CAN-16-3502. Epub 2017 Jun 30.
248	Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.Int J Cancer. 2018 Jun 1;142(11):2394-2404. doi: 10.1002/ijc.31308. Epub 2018 Mar 1.
249	Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.J Natl Cancer Inst. 2007 Nov 21;99(22):1668-82. doi: 10.1093/jnci/djm208. Epub 2007 Nov 13.
250	Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells.Thorac Cancer. 2018 Nov;9(11):1366-1375. doi: 10.1111/1759-7714.12839. Epub 2018 Sep 9.
251	Advances in antibody therapeutics targeting small-cell lung cancer.Adv Clin Exp Med. 2018 Sep;27(9):1317-1323. doi: 10.17219/acem/70159.
252	Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus.Oncol Rep. 2014 Nov;32(5):1772-8. doi: 10.3892/or.2014.3436. Epub 2014 Aug 22.
253	Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.J Proteome Res. 2006 Mar;5(3):643-50. doi: 10.1021/pr050460x.
254	Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line.Cell Physiol Biochem. 2018;51(6):2938-2954. doi: 10.1159/000496045. Epub 2018 Dec 14.
255	Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.Diagn Cytopathol. 2016 Apr;44(4):299-304. doi: 10.1002/dc.23442. Epub 2016 Jan 22.
256	Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers.BMC Genet. 2004 Sep 2;5:27. doi: 10.1186/1471-2156-5-27.
257	Lentivirus-mediated knockdown of NLK inhibits small-cell lung cancer growth and metastasis.Drug Des Devel Ther. 2016 Nov 15;10:3737-3746. doi: 10.2147/DDDT.S87435. eCollection 2016.
258	Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung.J Thorac Oncol. 2006 Oct;1(8):780-6.
259	Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.BMC Cancer. 2012 Sep 24;12:422. doi: 10.1186/1471-2407-12-422.
260	Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.Oncotarget. 2017 Dec 26;9(4):5197-5207. doi: 10.18632/oncotarget.23708. eCollection 2018 Jan 12.
261	Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.Mol Cancer Ther. 2019 Nov;18(11):1926-1936. doi: 10.1158/1535-7163.MCT-19-0022.
262	Loss of the integrin-activating transmembrane protein Fam38A (Piezo1) promotes a switch to a reduced integrin-dependent mode of cell migration.PLoS One. 2012;7(7):e40346. doi: 10.1371/journal.pone.0040346. Epub 2012 Jul 5.
263	Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Oncotarget. 2015 Sep 22;6(28):24690-8. doi: 10.18632/oncotarget.3992.
264	Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.Pathol Int. 2014 Sep;64(9):415-22. doi: 10.1111/pin.12198.
265	Genetic and Functional Analysis of Polymorphisms in the Human Dopamine Receptor and Transporter Genes in Small Cell Lung Cancer.J Cell Physiol. 2016 Feb;231(2):345-56. doi: 10.1002/jcp.25079.
266	Proliferation of small cell lung cancer cell line reduced by knocking-down PROX1 via shRNA in lentivirus.Anticancer Res. 2013 Aug;33(8):3169-75.
267	Detection of drug-resistance genes using single bronchoscopy biopsy specimens.Oncol Rep. 2007 Sep;18(3):703-8.
268	Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer.J Hematol Oncol. 2015 Jun 11;8:67. doi: 10.1186/s13045-015-0164-y.
269	RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.PLoS One. 2017 Jun 29;12(6):e0180258. doi: 10.1371/journal.pone.0180258. eCollection 2017.
270	The effect of RCAN1 on the biological behaviors of small cell lung cancer.Tumour Biol. 2017 Jun;39(6):1010428317700405. doi: 10.1177/1010428317700405.
271	TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).Sci Rep. 2017 Mar 28;7:45351. doi: 10.1038/srep45351.
272	Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.Genes Chromosomes Cancer. 2013 Sep;52(9):802-16. doi: 10.1002/gcc.22076. Epub 2013 May 28.
273	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18.
274	Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain.FASEB J. 2019 Feb;33(2):1742-1757. doi: 10.1096/fj.201800428R. Epub 2018 Sep 5.
275	Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494.Oncotarget. 2014 Sep 15;5(17):7760-75. doi: 10.18632/oncotarget.2305.
276	Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer.Biosci Biotechnol Biochem. 2005 Jan;69(1):56-62. doi: 10.1271/bbb.69.56.
277	Identification and characterization of the first fragment hits for SETDB1 Tudor domain.Bioorg Med Chem. 2019 Sep 1;27(17):3866-3878. doi: 10.1016/j.bmc.2019.07.020. Epub 2019 Jul 12.
278	CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.Cancer Res. 2014 Mar 1;74(5):1554-65. doi: 10.1158/0008-5472.CAN-13-1541. Epub 2014 Jan 16.
279	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor.J Endocrinol. 2008 Sep;198(3):499-509. doi: 10.1677/JOE-08-0019. Epub 2008 Jun 26.
280	Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma.J Cancer Res Clin Oncol. 2019 May;145(5):1361-1367. doi: 10.1007/s00432-019-02848-9. Epub 2019 Mar 21.
281	Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.Oncol Rep. 2009 Jun;21(6):1367-72. doi: 10.3892/or_00000362.
282	WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway.Br J Cancer. 2016 Jul 12;115(2):243-51. doi: 10.1038/bjc.2016.186. Epub 2016 Jun 23.
283	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival.Cancer Sci. 2013 Feb;104(2):171-7. doi: 10.1111/cas.12068. Epub 2013 Jan 7.
284	Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.PLoS One. 2014 Jun 24;9(6):e100249. doi: 10.1371/journal.pone.0100249. eCollection 2014.
285	TRIB2 contributes to cisplatin resistance in small cell lung cancer.Oncotarget. 2017 Nov 27;8(65):109596-109608. doi: 10.18632/oncotarget.22741. eCollection 2017 Dec 12.
286	Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes.Ann Clin Transl Neurol. 2017 Jul 28;4(9):680-686. doi: 10.1002/acn3.396. eCollection 2017 Sep.
287	TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.Biochem Biophys Res Commun. 2017 Apr 29;486(2):349-356. doi: 10.1016/j.bbrc.2017.03.044. Epub 2017 Mar 14.
288	Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.J Natl Cancer Inst. 1992 Nov 18;84(22):1710-6. doi: 10.1093/jnci/84.22.1710.
289	The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer.Anticancer Res. 2015 Mar;35(3):1663-7.
290	ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.Cancer Res. 2017 Nov 15;77(22):6267-6281. doi: 10.1158/0008-5472.CAN-17-0570. Epub 2017 Sep 21.
291	Clinical significance of serum miR-25 in non-small-cell lung cancer.Br J Biomed Sci. 2019 Jul;76(3):111-116. doi: 10.1080/09674845.2019.1592915. Epub 2019 May 14.
292	Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.Exp Mol Pathol. 2010 Jun;88(3):401-6. doi: 10.1016/j.yexmp.2010.02.003. Epub 2010 Mar 4.
293	Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis.Ann Diagn Pathol. 2018 Jun;34:1-12. doi: 10.1016/j.anndiagpath.2017.11.011. Epub 2017 Nov 29.
294	Corticotropin-releasing factor receptors in human small cell lung carcinoma cells: radioligand binding, second messenger, and northern blot analysis data.Endocrinology. 1994 Oct;135(4):1551-8. doi: 10.1210/endo.135.4.7925116.
295	Expression of a splicing variant of the CADM1 specific to small cell lung cancer.Cancer Sci. 2012 Jun;103(6):1051-7. doi: 10.1111/j.1349-7006.2012.02277.x. Epub 2012 May 15.
296	Capsaicin displays anti-proliferative activity against human small cell lung cancer in cell culture and nude mice models via the E2F pathway.PLoS One. 2010 Apr 20;5(4):e10243. doi: 10.1371/journal.pone.0010243.
297	Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.Theranostics. 2017 Apr 10;7(6):1612-1632. doi: 10.7150/thno.17573. eCollection 2017.
298	A 2.5-Mb physical map within 3p21.1 spans the breakpoint associated with Greig cephalopolysyndactyly syndrome.Genomics. 1991 Sep;11(1):93-102. doi: 10.1016/0888-7543(91)90105-n.
299	Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.Proteomics Clin Appl. 2018 Nov;12(6):e1800015. doi: 10.1002/prca.201800015. Epub 2018 Jul 5.
300	P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens.Ann Diagn Pathol. 2018 Apr;33:23-29. doi: 10.1016/j.anndiagpath.2017.11.008. Epub 2017 Nov 11.
301	Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.Integr Cancer Ther. 2018 Dec;17(4):1109-1114. doi: 10.1177/1534735418801532. Epub 2018 Sep 19.
302	Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer.Medicine (Baltimore). 2019 Aug;98(31):e16712. doi: 10.1097/MD.0000000000016712.
303	Evolution of chromosomal alterations and biologic features in two small cell lung carcinoma cell lines established from one patient during the course of the disease.Cancer Genet Cytogenet. 1995 Mar;80(1):47-54. doi: 10.1016/0165-4608(94)00154-4.
304	RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.Am J Transl Res. 2017 Feb 15;9(2):674-682. eCollection 2017.
305	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.Cancer Res. 2018 Jul 1;78(13):3709-3717. doi: 10.1158/0008-5472.CAN-18-0161. Epub 2018 May 14.
306	Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells.Lung Cancer. 1996 Nov;15(3):341-54. doi: 10.1016/0169-5002(95)00597-8.
307	High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO?Au Nanocomposite.Molecules. 2019 Feb 13;24(4):656. doi: 10.3390/molecules24040656.
308	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.Oncogene. 2006 Feb 9;25(6):959-68. doi: 10.1038/sj.onc.1209115.
309	The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.PLoS One. 2014 Nov 6;9(11):e111651. doi: 10.1371/journal.pone.0111651. eCollection 2014.
310	FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer.Clin Cancer Res. 2019 Feb 15;25(4):1302-1317. doi: 10.1158/1078-0432.CCR-18-1447. Epub 2018 Nov 14.
311	Flotillin1 promotes EMT of human small cell lung cancer via TGF- signaling pathway.Cancer Biol Med. 2018 Nov;15(4):400-414. doi: 10.20892/j.issn.2095-3941.2018.0053.
312	Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells.Cancer Res. 2004 Oct 1;64(19):6874-82. doi: 10.1158/0008-5472.CAN-04-0633.
313	D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo.Br J Cancer. 2011 Jun 28;105(1):74-82. doi: 10.1038/bjc.2011.170. Epub 2011 Jun 7.
314	Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer.Cancer Manag Res. 2019 Jul 16;11:6637-6649. doi: 10.2147/CMAR.S199175. eCollection 2019.
315	A new small cell lung cancer biomarker identified by Cell-SELEX generated aptamers.Exp Cell Res. 2019 Sep 15;382(2):111478. doi: 10.1016/j.yexcr.2019.06.023. Epub 2019 Jun 21.
316	H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR.Ann Transl Med. 2018 Nov;6(22):440. doi: 10.21037/atm.2018.10.21.
317	Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.J Natl Cancer Inst. 1995 Nov 15;87(22):1674-80. doi: 10.1093/jnci/87.22.1674.
318	Tumor cell expression of heat shock protein (HSP) 72 is influenced by HSP72 [HSPA1B A(1267)G] polymorphism and predicts survival in small Cell lung cancer (SCLC) patients.Cancer Invest. 2012 May;30(4):317-22. doi: 10.3109/07357907.2012.657815. Epub 2012 Apr 2.
319	The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.Oncotarget. 2016 Aug 23;7(34):54596-54615. doi: 10.18632/oncotarget.10519.
320	Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response.Clin Cancer Res. 1999 Mar;5(3):673-80.
321	LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.Oncotarget. 2018 Jul 3;9(51):29601-29618. doi: 10.18632/oncotarget.25642. eCollection 2018 Jul 3.
322	Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis.Oncol Lett. 2019 Oct;18(4):3723-3733. doi: 10.3892/ol.2019.10685. Epub 2019 Jul 29.
323	Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer.Cancer Res. 1992 Apr 1;52(7):1996-9.
324	MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC).Med Sci Monit. 2018 Oct 22;24:7541-7547. doi: 10.12659/MSM.909772.
325	PACAP stimulates c-fos mRNAs in small cell lung cancer cells.Life Sci. 1996;59(4):307-13. doi: 10.1016/0024-3205(96)00299-8.
326	NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer.Oncotarget. 2016 Sep 6;7(36):57514-57524. doi: 10.18632/oncotarget.11583.
327	Small cell lung cancer mimicking lymphoma in CT and 68Ga-DOTA-NOC PET/CT: A case report.Medicine (Baltimore). 2018 Jun;97(25):e11159. doi: 10.1097/MD.0000000000011159.
328	Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.Cancer Res. 2010 May 15;70(10):3877-83. doi: 10.1158/0008-5472.CAN-09-4228. Epub 2010 Apr 20.
329	Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.Lung Cancer. 2005 Dec;50(3):329-37. doi: 10.1016/j.lungcan.2005.06.011. Epub 2005 Aug 22.
330	SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.Am J Surg Pathol. 2019 Apr;43(4):455-465. doi: 10.1097/PAS.0000000000001188.
331	Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.Mol Cancer Res. 2004 Sep;2(9):489-94.
332	PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.Lab Invest. 2009 Mar;89(3):301-14. doi: 10.1038/labinvest.2008.168. Epub 2009 Jan 12.
333	Characterization of human prodynorphin gene transcripts.Biochem Biophys Res Commun. 1995 Oct 24;215(3):881-8. doi: 10.1006/bbrc.1995.2546.
334	Expression of preprodynorphin in human small cell lung carcinoma cell lines.Regul Pept. 1991 Jul 9;34(3):181-8. doi: 10.1016/0167-0115(91)90177-i.
335	Nonspecific increased serum levels of secretory component in lung tumors: relationship to the gene expression of the transmembrane receptor form.Am J Respir Cell Mol Biol. 1993 Sep;9(3):341-6. doi: 10.1165/ajrcmb/9.3.341.
336	Mitogenic effect of the 15-kDa gross cystic disease fluid protein (GCDFP-15) on breast-cancer cell lines and on immortal mammary cells.Int J Cancer. 1995 Jan 17;60(2):216-20. doi: 10.1002/ijc.2910600215.
337	Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.Mol Cancer. 2013 Mar 2;12:16. doi: 10.1186/1476-4598-12-16.
338	Regulation of DNA polymerase POLD4 influences genomic instability in lung cancer.Cancer Res. 2010 Nov 1;70(21):8407-16. doi: 10.1158/0008-5472.CAN-10-0784. Epub 2010 Sep 22.
339	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9.
340	Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.Am J Pathol. 2015 Dec;185(12):3164-77. doi: 10.1016/j.ajpath.2015.08.018. Epub 2015 Oct 23.
341	Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.Oncogene. 1998 Jan 8;16(1):89-93. doi: 10.1038/sj.onc.1201512.
342	Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1488-94. doi: 10.1152/ajplung.00147.2006. Epub 2007 Feb 23.
343	Molecular abnormalities in lung cancer.J Clin Oncol. 1998 Mar;16(3):1207-17. doi: 10.1200/JCO.1998.16.3.1207.
344	NSP-encoded reticulons are neuroendocrine markers of a novel category in human lung cancer diagnosis.Cancer Res. 1994 Sep 1;54(17):4769-76.
345	Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.Oncotarget. 2017 Mar 21;8(12):18901-18913. doi: 10.18632/oncotarget.14782.
346	The Epithelial Sodium Channel (ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.Transl Oncol. 2018 Apr;11(2):292-299. doi: 10.1016/j.tranon.2018.01.004. Epub 2018 Feb 2.
347	Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers.PLoS One. 2015 May 11;10(5):e0123369. doi: 10.1371/journal.pone.0123369. eCollection 2015.
348	Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice.Cancer Res. 2002 May 1;62(9):2637-43.
349	Primary or salvage stereotactic radiosurgery for brain metastatic small cell lung cancer.J Neurooncol. 2019 Aug;144(1):217-225. doi: 10.1007/s11060-019-03224-w. Epub 2019 Jun 22.
350	SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.Mol Cancer Res. 2018 Dec;16(12):1819-1825. doi: 10.1158/1541-7786.MCR-18-0368. Epub 2018 Jul 23.
351	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations.Front Immunol. 2019 Apr 12;10:769. doi: 10.3389/fimmu.2019.00769. eCollection 2019.
352	SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).Future Oncol. 2015;11(7):1027-36. doi: 10.2217/fon.15.18.
353	Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer.Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203. doi: 10.1073/pnas.97.8.4198.
354	A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer.Sci Rep. 2019 May 20;9(1):7618. doi: 10.1038/s41598-019-43100-1.
355	Antitumor activity of SR splicing-factor 5 knockdown by downregulating pyruvate kinase M2 in non-small cell lung cancer cells.J Cell Biochem. 2019 Oct;120(10):17303-17311. doi: 10.1002/jcb.28992. Epub 2019 May 20.
356	IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.J Exp Clin Cancer Res. 2017 Oct 11;36(1):140. doi: 10.1186/s13046-017-0608-z.
357	Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.Cancer Immunol Immunother. 2007 Aug;56(8):1143-52. doi: 10.1007/s00262-006-0263-2. Epub 2006 Dec 2.
358	Expression of TLE-1 and CD99 in Carcinoma: Pitfalls in Diagnosis of Synovial Sarcoma.Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):368-373. doi: 10.1097/PAI.0000000000000436.
359	Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients.Anticancer Res. 2006 Mar-Apr;26(2B):1567-75.
360	Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol. 2010 Sep;75(3):173-234. doi: 10.1016/j.critrevonc.2009.11.006. Epub 2010 Jan 4.
361	Prognostic significance of folate metabolism polymorphisms for lung cancer.Br J Cancer. 2007 Jul 16;97(2):247-52. doi: 10.1038/sj.bjc.6603830. Epub 2007 May 29.
362	Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.Oncol Rep. 2006 May;15(5):1281-5.
363	Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells.Am J Respir Cell Mol Biol. 1999 Apr;20(4):543-9. doi: 10.1165/ajrcmb.20.4.3406.
364	Seizure 6-like (SEZ6L) gene and risk for lung cancer.Cancer Res. 2007 Sep 1;67(17):8406-11. doi: 10.1158/0008-5472.CAN-06-4784.
365	Identification of key modules and hub genes for small-cell lung carcinoma and large-cell neuroendocrine lung carcinoma by weighted gene co-expression network analysis of clinical tissue-proteomes.PLoS One. 2019 Jun 5;14(6):e0217105. doi: 10.1371/journal.pone.0217105. eCollection 2019.